In summary, GKRP variants such as P446L chronically enhance hepatocyte glucose metabolism, increasing lipogenesis and risk of MASLD while paradoxically lowering fasting glucose and insulin resistance risk. Here, GCKR is linked to metabolic dysfunction-associated steatotic liver disease.